Lexicon Pharmaceuticals, Inc. - Laporan Laba Rugi (TTM)

Lexicon Pharmaceuticals, Inc.
US ˙ NasdaqCM ˙ US5288723027

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Lexicon Pharmaceuticals, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 33 24 16 7 0 0 0 0 0 0 0 0 1 1 2 4 5 31 31 58
Change (%) -26.22 -33.22 -55.73 -93.19 -38.30 3.36 -64.61 14.68 11.20 -9.35 223.02 30.22 127.17 91.86 57.62 43.61 494.40 0.42 87.20
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 193 153 110 62 40 55 57 60 55 53 50 51 58 59 49 36 44 84 84 84
Change (%) -20.88 -28.19 -43.46 -36.37 39.22 4.21 5.40 -8.48 -5.10 -4.95 2.39 13.71 1.47 -17.64 -26.16 23.10 90.24 -0.03 -0.23
% of Revenue 594.77 637.84 685.95 875.92 8,186.34 18,471.81 18,624.35 55,469.72 44,269.60 37,781.29 39,615.87 12,557.49 10,965.47 4,898.01 2,102.64 985.09 844.39 270.25 269.04 143.39
Gross Operating Profit -161 -129 -94 -55 -39 -55 -57 -60 -55 -52 -50 -51 -58 -58 -46 -32 -39 -53 -53 -25
Change (%) -19.80 -27.25 -41.37 -29.04 40.17 4.21 5.78 -8.52 -5.13 -4.94 1.83 13.58 0.31 -19.92 -30.34 20.78 35.94 -0.29 -51.95
% of Revenue -494.77 -537.84 -585.95 -775.92 -8,086.34 -18,371.81 -18,524.35 -55,369.72 -44,169.60 -37,681.29 -39,515.87 -12,457.49 -10,865.47 -4,798.01 -2,002.64 -885.09 -744.39 -170.25 -169.04 -43.39
SG&A 52 44 38 32 30 32 33 35 41 48 59 78 98 113 125 135 142 132 111 82
Change (%) -15.53 -14.54 -16.34 -5.36 8.07 0.72 8.44 14.93 18.43 22.15 32.90 25.18 15.19 11.48 7.32 5.47 -7.12 -15.51 -26.78
% of Revenue 161.00 184.33 235.90 445.76 6,196.27 10,853.02 10,576.62 32,409.17 32,480.00 34,592.09 46,612.70 19,177.64 18,434.72 9,347.34 5,431.26 3,698.08 2,715.83 424.38 357.06 139.66
R&D 13 29 29 1 -1
Change (%) 124.93 0.00 -193.17
% of Revenue 553.16 789.40 549.67 3.05 -1.52
OpEx 246 197 148 94 69 87 90 96 96 101 109 129 156 172 187 199 215 216 196 165
Change (%) -19.74 -25.13 -36.52 -25.91 25.80 2.92 6.50 0.16 4.86 8.00 18.88 20.64 10.07 8.92 6.66 7.85 0.46 -9.04 -16.23
% of Revenue 755.77 822.17 921.86 1,321.68 14,382.61 29,324.83 29,200.97 87,878.90 76,749.60 72,373.38 86,228.57 31,735.14 29,400.19 14,245.35 8,087.06 5,472.56 4,109.89 694.63 629.15 281.53
Operating Income -213 -173 -132 -87 -69 -87 -90 -96 -96 -100 -109 -129 -155 -170 -185 -196 -210 -185 -165 -106
Change (%) -18.75 -24.01 -34.19 -20.40 26.24 2.92 6.75 0.14 4.85 8.03 18.64 20.61 9.67 8.33 6.02 7.19 -11.86 -10.63 -35.78
% of Revenue -655.77 -722.17 -821.86 -1,221.68 -14,282.61 -29,224.83 -29,100.97 -87,778.90 -76,649.60 -72,273.38 -86,128.57 -31,635.14 -29,300.19 -14,145.35 -7,987.06 -5,372.56 -4,009.89 -594.63 -529.15 -181.53
Interest Expense -20 -15 -10 -5 -1 -1 -1 -1 -2 -3 -4 -6 -9 -13 -16 -16 -17 -16 -12 -13
Change (%) -25.66 -34.13 -51.73 -85.36 18.46 -7.11 71.68 54.18 40.97 61.55 27.99 52.80 49.16 23.87 1.55 4.02 -9.12 -19.98 0.86
% of Revenue -60.16 -60.61 -59.79 -65.18 -140.17 -269.13 -241.88 -1,173.39 -1,577.60 -2,000.00 -3,564.29 -1,412.29 -1,657.17 -1,088.12 -702.51 -452.60 -327.83 -50.12 -39.94 -21.52
Net Income -104 -59 -13 38 -68 -88 -90 -97 -97 -102 -110 -131 -158 -177 -194 -202 -216 -200 -177 -121
Change (%) -43.80 -77.94 -394.74 -277.62 29.74 2.87 7.22 0.27 5.03 8.30 18.40 20.76 12.20 9.29 4.40 7.07 -7.39 -11.53 -31.97
% of Revenue -320.44 -244.11 -80.64 536.83 -14,004.55 -29,448.99 -29,310.39 -88,803.67 -77,648.80 -73,341.01 -87,620.63 -32,117.69 -29,784.34 -14,710.88 -8,380.17 -5,550.87 -4,138.32 -644.78 -568.04 -206.43

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista